Major Vault Protein Suppresses Lung Cancer Cell Proliferation By
Total Page:16
File Type:pdf, Size:1020Kb
Bai et al. BMC Cancer (2019) 19:454 https://doi.org/10.1186/s12885-019-5665-6 RESEARCH ARTICLE Open Access Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway Hui Bai1†, Chenchen Wang1†,YuQi1†, Jin Xu3, Nan Li1,2, Lili Chen1, Bin Jiang1, Xudong Zhu1, Hanwen Zhang1, Xiaoyu Li1, Qing Yang1, Junqing Ma1, Yong Xu1, Jingjing Ben1* and Qi Chen1* Abstract Background: Major vault protein (MVP) is the major component of vault, a eukaryotic organelle involved in multiple cellular processes, and is important in multiple cellular processes and diseases including the drug resistance in cancer chemotherapies. However, the role of MVP in lung cancer remains unclear. Methods: We examined MVP expression in 120 non-small cell lung cancer (NSCLC) tumors and matched normal tissues by immunohistochemistry. Its relationship with NSCLC prognosis was determined by investigating the patient cohort and analyzing the data from a published dataset consisting with more than 1900 lung cancer patients. We further performed shRNA-introduced knockdown of MVP in Lewis lung carcinoma (LLC) cells and examined its effects on the tumor formation in a xenograft mouse model and the tumor cell proliferation, apoptosis, and signal transduction in vitro. Results: We found that MVP was up-regulated significantly in tumor tissues compared with the matched tumor- adjacent normal tissues. The increased expression of MVP in lung adenocarcinoma was associated with a better prognosis. Knockdown of MVP in LLC cells promoted xenografted lung cancer formation in mice, which was accompanied with accelerated tumor cell proliferation and suppressed cell apoptosis in vitro. Knockdown of MVP stimulated STAT3 phosphorylation, nuclear localization, and activation of JAK2 and RAF/MEK/ERK pathways in LLC cells. Administration of STAT3 inhibitor WP1066 could prevent MVP knockdown induced tumorigenesis. Conclusions: Our findings demonstrate that MVP may act as a lung tumor suppressor via inhibiting STAT3 pathway. MVP would be a potential target for novel therapies of lung adenocarcinoma. Keywords: Non-small cell lung cancer, Major vault protein, STAT3, Cell proliferation, Cell apoptosis Background identification of novel biomarkers and targets are useful in Lung cancer is one of the most common cancers and the developing new therapeutic options for NSCLC. leading cause of cancer related death [1]. Non-small cell Major vault protein (MVP), also known as lung resistant lung cancer (NSCLC) accounts for about 80% of diag- protein (LRP), is ubiquitously expressed in most animal nosed patients with lung cancer [2]. Despite the progress cells. It is the major component of vault that is the largest on targeted therapies [3, 4], understanding the compli- known ribonucleoprotein particle in cytoplasm [5]. cated pathogenesis mechanisms is still limited. Moreover, Current studies indicate that vault is involved in a broad rapid progression on drug resistance affects the effective- range of cellular processes, including nuclear pore assem- ness of chemotherapies and targeted therapies. Thus, bly, subcellular transportation, cell signaling, and inter- feron response [5–8]. Although MVP is overexpressed in the drug-resistant cancer cells [9–11], the definite role of * Correspondence: [email protected]; [email protected] † it in NSCLC is still a disputable issue [12, 13]. Janikova Hui Bai, Chenchen Wang and Yu Qi contributed equally to this work. 1Department of Pathophysiology, Key Laboratory of Cardiovascular Disease et al. reported that the MVP expression is of prognostic and Molecular Intervention, Nanjing Medical University, Nanjing, China significance in NSCLC when examined in combination Full list of author information is available at the end of the article © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Bai et al. BMC Cancer (2019) 19:454 Page 2 of 13 with miR-23b [14]. MVP is required for the nuclear wasrecordedas1–4(1,0–25%;2,26–50%;3,51–75%; 4, localization of tumor suppressor PTEN [15, 16], which 76–100%). The IRS was calculated by multiple the intensity down-regulates cyclin D1, prevents the phosphorylation of and percentage of immunoreactive cells. Wilcoxon test (raw MAPK, and leads to cell cycle arrest [17]. MVP also binds scores) was applied to determine the significance of MVP to HIF1α and promotes the degradation of HIF1α.Itsup- staining in primary lung tumors compared with the matched ports the notion that MVP may function as a tumor sup- adjacent tumoral tissues.Mousetumortissueswere pressor in renal adenocarcinoma cells [18]. Yet, MVP also formalin-fixed, paraffin-embedded, and sectioned. Immuno- promotes survival and migration of glioblastoma [19], and histochemistry (IHC) of mouse tissue sections was con- suppresses apoptosis of human senescent diploid fibroblasts ducted with antibodies against Ki67 and CD31 (Abcam). [20] and human colon cancer cells [21]. These inconsistent results suggest that insighted mechanistic researches on the Animal experiments role of MVP in cancer are absolutely necessary. All aspects of the animal care and experimental proto- By examining 120 patients with NSCLC, we found that cols were approved by Nanjing Medical University Com- MVP expression was significantly up-regulated in cancer mittee on Animal Care. The C57BL/6 J mice were tissues compared with the paired normal tissues. Higher purchased from Animal Core Facility of Nanjing Medical MVP expression was correlated with better clinical out- University and kept in animal care facilities under comes in patients with lung cancer, especially in patients pathogen-free conditions. Tumor xenograft assays were with adenocarcinoma. When MVP was knocked down performed with 6 to 8-week-old mice. Briefly, 5 × 106 in Lewis lung carcinoma (LLC) cells and the MVP sup- tumor cells per site were suspended in 0.1 ml PBS and pressed LLC cells were injected subcutaneously into subcutaneous injected into mice. After 3 weeks, mice mice, it promoted lung cancer growth and the tumor were euthanized by carbon dioxide, and tumors were cell apoptosis was inhibited. This was causally linked to dissected for determining the size and weight, followed the activation of STAT3 signaling pathway. Our findings by IHC staining and flow cytometry analysis. Tumor vol- suggest that MVP act as a NSCLC suppressor which ume was calculated using the formula: volume = may be useful for discovery of novel therapy. 0.5236 × length × width2. Methods Cell culture Patient cohort and tissue collection The mouse Lewis lung carcinoma (LLC) and human This study was approved by the Institution Review lung adenocarcinoma SPC-A1 cells (Chinese Academy Board of Bengbu Medical College and Nanjing Medical of Science) were cultured in DMEM medium containing University. Patients were recruited from 2011 to 2013 in 10% FBS with the supply of 5% CO2. To generate stable the First Affiliated Hospital of Bengbu Medical College. knockdown cells, the lenti-viruses including hairpin The cohort is composed of 44 patients with adenocar- (Genepharma, China) were used to infect LLC cells. cinoma and 76 patients with squamous cell carcinomas After infecting for 24 h, cells were selected by 8 μg/ml without previous lung cancer history or preoperative puromycin for at least 2 weeks before conducting exper- chemotherapy and radiotherapy. iments. The hairpins sequences against mouse MVP The lung cancer samples and matched noncancerous were: shRNA-MVP1, CATAAGAACTCAGCACGTATT- lung tissues (more than 5 cm from the tumoral margins) CAAGAGATACGTGCTGAGTTCTTATG; shRNA- were applied for the tissue microarray (TMA) construc- MVP2, CCATCGAAACTGCAGATCATTCAAGAGAT- tion. The TMAs were created by contract service at GATCTGCAGTTTCGATGG. The hairpin sequence Shanghai OUTDO Biotech, China. Duplicate 1.0-mm against human MVP was: shRNA-hMVP, GGTG diameter cores of tissue from each sample were punched CTGTTTGATGTCACATTCAAGAGATGTGACATCA from paraffin tumor block and corresponding nontu- AACAGCACC. moral tissues. As a tissue control, the biopsies of normal lung tissues were inserted in the angles of each slide. Cell proliferation and apoptosis analyses Cell proliferation assays were evaluated by the cell count- Immunohistochemistry ing kit-8 assay (CCK-8) (Dojindo Laboratories, Kuma- The MVP antibody (1:100 dilution, Santa Cruz) was used to moto, Japan). Briefly, 2 × 103 cells were seeded in 96-well determine the protein expression levels. The goat IgG served plates and cultured for 1 to 6 days. Then, the CCK-8 as- as a negative control. The immunoreactivity score (IRS) were says were conducted according to the instruction followed evaluated by two pathologists independently using the fol- by 450 nm absorbance measurement using a plate reader. lowing semiquantitative criterion: the intensity of immuno- For colony formation assays, cells were seeded in 10 staining was recorded as 0–3(0,negative;1,weak;2, cm-plates at a density of 200 cells per plate. After cultur- moderate; 3, strong); the percentage